Thursday, September 20, 2007

CG Therapeutics Appoints Chairman, Looks For Venture Funding

Biotechnology firm CG Therapeutics announced today that it has named Christopher S. Henney, Ph.D., D.Sc., as chairman of its board of directors. CG Therapeutics described Henney as a biotechnology entrepreneur and scientist who co-founded and helped lead three public biotechnology companies—Immunex, ICOS and Dendreon. He joins CG Therapeutics as it awaits comprehensive Phase 2 clinical trails of CG201, a proprietary cancer vaccine. The Seattle-based company said it plans to complete a Series A round of venture financing in order to fund those trials. In addition to chairing CG Therapeutics, Henney also chairs Biomira and SGX Pharmaceuticals, CG Therapeutics said.